Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All PPI studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPPIsPPIs (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

What is the role of proton pump inhibitors consumption on the clinical presentation and severity of COVID-19 infection?

Shokri et al., Annales Pharmaceutiques Françaises, doi:10.1016/j.pharma.2022.08.013
Mar 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Severe case, all patients -81% Improvement Relative Risk Severe case, short-term -138% Severe case, long-term -30% Mortality -78% unadjusted PPIs for COVID-19  Shokri et al.  Prophylaxis Is prophylaxis with PPIs beneficial for COVID-19? Retrospective 670 patients in Iran (September 2021 - January 2022) Higher severe cases with PPIs (p=0.046) c19early.org Shokri et al., Annales Pharmaceutiques.., Mar 2023 FavorsPPI Favorscontrol 0 0.5 1 1.5 2+
PPIs for COVID-19
1st treatment shown to increase risk in September 2020
 
*, now with p = 0.00000019 from 38 studies.
* From meta analysis with ≥3 studies.
5,000+ studies for 104 treatments. c19early.org
Retrospective 670 COVID-19 patients in Iran showing significantly higher COVID-19 severity scores and more symptomatic presentation in patients with a history of proton pump inhibitor (PPI) use. Adjusted results are only provided for severity. Several values in Table 4 are likely misreported raising concern for the reliability of the main result.
This study is excluded in the after exclusion results of meta analysis: potential data issue.
risk of severe case, 81.0% higher, RR 1.81, p = 0.046, treatment 121, control 549, all patients.
risk of severe case, 137.6% higher, OR 2.38, p < 0.001, treatment 40, control 549, short-term, RR approximated with OR.
risk of severe case, 30.5% higher, OR 1.30, p = 0.36, treatment 81, control 549, long-term, RR approximated with OR.
risk of death, 78.0% higher, RR 1.78, p = 0.21, treatment 8 of 113 (7.1%), control 21 of 528 (4.0%), unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shokri et al., 31 Mar 2023, retrospective, Iran, peer-reviewed, mean age 44.2, 6 authors, study period 10 September, 2021 - 18 January, 2022. Contact: mohammadalishokri@yahoo.com, shokri.ma@iums.ac.ir, mfd@yahoo.com, moghadamfard.t@iums.ac.ir, ramim.t@iums.ac.ir, alireza.hejrati@gmail.com, lina1381@gmail.com, marjanmokhtare@yahoo.com, m.mokhtare@iums.ac.ir.
This PaperPPIsAll
What is the role of proton pump inhibitors consumption on the clinical presentation and severity of COVID-19 infection?
M A Shokri, T Moghadam Fard, T Ramim, A Hejrati, L Hejrati, M Mokhtare
Annales Pharmaceutiques Françaises, doi:10.1016/j.pharma.2022.08.013
The COVID-19 severity scores (qCSI) were significantly higher in PPI users compared to non-users, in population with no comorbidity (Charlson Comorbidity Index = 0). • Mortality rate wasn't significantly different between PPI-users and non-users. • All three types of COVID-19 symptoms investigated in this study (flu-like, respiratory and gastrointestinal) manifested more in PPI users than non-users.
Author contribution All authors had access to the data and a role in data gathering and writing the manuscript. Disclosure of interest The authors declare that they have no competing interest.
References
Almario, Chey, Spiegel, Increased risk of COVID-19 among users of proton pump inhibitors, Am J Gastroenterol
Alzubaidi, Gabbard, GERD: Diagnosing and treating the burn, Cleve Clin J Med
Antunes, Curtis, Gastroesophageal Reflux Disease
Bagherzadeh, Safari, Amanlou, Motevalian, Proton pump inhibitors in Iranian population: from clinical regimens to pharmacogenomics, Physiol Pharmacol
Blanc, Waechter, Vogel, Schorr, Demuynck et al., Therapeutic prevention of COVID-19 in elderly: a case-control study, Geroscience
Blanco, Ambrosioni, Garcia, Martínez, Soriano et al., COVID-19 in patients with HIV: clinical case series, Lancet HIV
Dadras, Afsahi, Pashaei, Mojdeganlou, Karimi et al., The relationship between COVID-19 viral load and disease severity: a systematic review, Immun Inflamm Dis
Domingo, Proton pump inhibitors in the COVID-19 pandemic. Gastroenterología y Hepatología
Fang, Li, Yu, Wang, Zhang et al., Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis, Aging
Gao, Ding, Dong, Zhang, Azkur et al., Risk factors for severe and critically ill COVID-19 patients: a review, Allergy
Grasselli, Greco, Zanella, Albano, Antonelli et al., Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy, JAMA Intern Med
Haimovich, Ravindra, Stoytchev, Young, Wilson et al., Development and validation of the quick COVID-19 Severity Index: a prognostic tool for early clinical decompensation, Ann Emerg Med
Hariyanto, Prasetya, Kurniawan, Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection, Dig Liver Dis
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell
Hoteit, Mattar, Allaw, Rached, Epidemiological study assessing the overuse of proton pump inhibitors in Lebanese population, Middle East J Dig Dis
Israelsen, Ernst, Lundh, Lundbo, Sandholdt et al., Proton Pump inhibitor use is not strongly associated with SARS-CoV-2 related outcomes: a nationwide study and meta-analysis, Clin Gastroenterol Hepatol
Izcovich, Ragusa, Tortosa, Marzio, Agnoletti et al., Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review, PLOS ONE
Kellerman, Kintanar, Gastroesophageal reflux disease, Prim Care
Khatami, Saatchi, Zadeh, Aghamir, Shabestari et al., A meta-analysis of accuracy and sensitivity of chest CT and RT-PCR in COVID-19 diagnosis, Sci Rep
Kow, Hasan, Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis, J Intern Med
Lai, Wang, Wang, Hsueh, Ko et al., Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status, Int J Antimicrob Agents
Lee, Ha, Yeniova, Moon, Kim et al., Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching, Gut
Lighter, Phillips, Hochman, Sterling, Johnson et al., Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission, Clin Infect Dis
Liu, Sloan, Owings, Figgins, Gauthier et al., Increased ACE2 levels and mortality risk of patients with COVID-19 on proton pump inhibitor therapy, Am J Gastroenterol
Mokhtare, Alimoradzadeh, Agah, Mirmiranpour, Khodabandehloo, The Association between modulating inflammatory cytokines and constipation of geriatrics in Iran, Middle East J Dig Dis
Novelli, Biancolella, Mehrian-Shai, Erickson, Pollitt et al., COVID-19 update: the first 6 months of the pandemic, Hum Genomics
Pranata, Huang, Lawrensia, Henrina, Lim et al., Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis, Pharmacol Rep
Quan, Li, Couris, Fushimi, Graham et al., Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries, Am J Epidemiol
Ramachandran, Perisetti, Gajendran, Louis, Bansal et al., Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19, Eur J Gastroenterol Hepatol
Raudenská, Steinerová, Javůrková, Urits, Kaye et al., Occupational burnout syndrome and posttraumatic stress among healthcare professionals during the novel coronavirus disease 2019 (COVID-19) pandemic, Best Pract Res Clin Anaesthesiol
Sung, Kuipers, El-Serag, Systematic review: the global incidence and prevalence of peptic ulcer disease, Aliment Pharmacol Ther
Tas ¸temur S ¸, Ataseven, Is it possible to use proton pump inhibitors in COVID-19 treatment and prophylaxis?, Med Hypotheses
Torres, Valencia, Sellares, PNEUMONIA | Nosocomial
Who, Archived: WHO Timeline -COVID-19
Yan, Chen, Sun, Ahmed, Bhan et al., Does proton pump inhibitor use lead to a higher risk of coronavirus disease 2019 infection and progression to severe disease? A meta-analysis, Jpn J Infect Dis
Yibirin, Oliveira, Valera, Plitt, Lutgen, Adverse effects associated with proton pump inhibitor use, Cureus
Younes, Al-Sadeq, Al-Jighefee, Younes, Daas, Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2, Viruses
Zhang, Kang, Gong, Xu, Wang et al., Digestive system is a potential route of COVID-19: an analysis of singlecell coexpression pattern of key proteins in viral entry process, Gut
Zhang, Li, Wu, Ling, Qian et al., Analysis of the effect of proton-pump inhibitors on the course of COVID-19, J Inflamm Res
Zippi, Fiorino, Budriesi, Micucci, Corazza et al., Paradoxical relationship between proton pump inhibitors and COVID-19: a systematic review and meta-analysis, World J Clin Cases
{ 'indexed': {'date-parts': [[2023, 3, 17]], 'date-time': '2023-03-17T03:41:04Z', 'timestamp': 1679024464574}, 'reference-count': 40, 'publisher': 'Elsevier BV', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2023, 3, 1]], 'date-time': '2023-03-01T00:00:00Z', 'timestamp': 1677628800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [ { 'DOI': '10.13039/100012021', 'name': 'Iran University of Medical Sciences', 'doi-asserted-by': 'publisher', 'award': ['IR.IUMS.FMD.REC.1400.403']}], 'content-domain': { 'domain': ['clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 3]]}, 'DOI': '10.1016/j.pharma.2022.08.013', 'type': 'journal-article', 'created': {'date-parts': [[2022, 8, 29]], 'date-time': '2022-08-29T15:52:59Z', 'timestamp': 1661788379000}, 'page': '210-219', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'What is the role of proton pump inhibitors consumption on the clinical presentation and severity ' 'of COVID-19 infection?', 'prefix': '10.1016', 'volume': '81', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6979-6375', 'authenticated-orcid': False, 'given': 'M.A.', 'family': 'Shokri', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0024-879X', 'authenticated-orcid': False, 'given': 'T.', 'family': 'Moghadam Fard', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8929-9357', 'authenticated-orcid': False, 'given': 'T.', 'family': 'Ramim', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0087-8385', 'authenticated-orcid': False, 'given': 'A.', 'family': 'Hejrati', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3736-7928', 'authenticated-orcid': False, 'given': 'L.', 'family': 'Hejrati', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4869-9442', 'authenticated-orcid': False, 'given': 'M.', 'family': 'Mokhtare', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '1', 'key': '10.1016/j.pharma.2022.08.013_bib0205', 'doi-asserted-by': 'crossref', 'first-page': '48', 'DOI': '10.1186/s40246-020-00298-w', 'article-title': 'COVID-19 update: the first 6 months of the pandemic', 'volume': '14', 'author': 'Novelli', 'year': '2020', 'journal-title': 'Hum Genomics'}, { 'issue': '4', 'key': '10.1016/j.pharma.2022.08.013_bib0210', 'doi-asserted-by': 'crossref', 'first-page': '105946', 'DOI': '10.1016/j.ijantimicag.2020.105946', 'article-title': 'Global epidemiology of coronavirus disease 2019 (COVID-19): disease ' 'incidence, daily cumulative index, mortality, and their association ' 'with country healthcare resources and economic status', 'volume': '55', 'author': 'Lai', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'issue': '10', 'key': '10.1016/j.pharma.2022.08.013_bib0215', 'doi-asserted-by': 'crossref', 'first-page': '1345', 'DOI': '10.1001/jamainternmed.2020.3539', 'article-title': 'Risk Factors Associated With Mortality Among Patients With COVID-19 in ' 'Intensive Care Units in Lombardy, Italy', 'volume': '180', 'author': 'Grasselli', 'year': '2020', 'journal-title': 'JAMA Intern Med'}, { 'issue': '15', 'key': '10.1016/j.pharma.2022.08.013_bib0220', 'doi-asserted-by': 'crossref', 'first-page': '896', 'DOI': '10.1093/cid/ciaa415', 'article-title': 'Obesity in patients younger than 60 years is a risk factor for COVID-19 ' 'hospital admission', 'volume': '71', 'author': 'Lighter', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'issue': '5', 'key': '10.1016/j.pharma.2022.08.013_bib0225', 'doi-asserted-by': 'crossref', 'first-page': 'e314', 'DOI': '10.1016/S2352-3018(20)30111-9', 'article-title': 'COVID-19 in patients with HIV: clinical case series', 'volume': '7', 'author': 'Blanco', 'year': '2020', 'journal-title': 'Lancet HIV'}, { 'key': '10.1016/j.pharma.2022.08.013_bib0230', 'series-title': 'Archived: WHO Timeline\xa0–\xa0COVID-19', 'author': 'WHO', 'year': '2020'}, { 'issue': '3', 'key': '10.1016/j.pharma.2022.08.013_bib0235', 'doi-asserted-by': 'crossref', 'first-page': '553', 'DOI': '10.1016/j.bpa.2020.07.008', 'article-title': 'Occupational burnout syndrome and post-traumatic stress among ' 'healthcare professionals during the novel coronavirus disease 2019 ' '(COVID-19) pandemic', 'volume': '34', 'author': 'Raudenská', 'year': '2020', 'journal-title': 'Best Pract Res Clin Anaesthesiol'}, { 'key': '10.1016/j.pharma.2022.08.013_bib0240', 'series-title': 'Gastroesophageal Reflux Disease. StatPearls [Internet]', 'author': 'Antunes', 'year': '2021'}, { 'issue': '9', 'key': '10.1016/j.pharma.2022.08.013_bib0245', 'doi-asserted-by': 'crossref', 'first-page': '938', 'DOI': '10.1111/j.1365-2036.2009.03960.x', 'article-title': 'Systematic review: the global incidence and prevalence of peptic ulcer ' 'disease', 'volume': '29', 'author': 'Sung', 'year': '2009', 'journal-title': 'Aliment Pharmacol Ther'}, { 'issue': '10', 'key': '10.1016/j.pharma.2022.08.013_bib0250', 'doi-asserted-by': 'crossref', 'first-page': '685', 'DOI': '10.3949/ccjm.82a.14138', 'article-title': 'GERD: Diagnosing and treating the burn', 'volume': '82', 'author': 'Alzubaidi', 'year': '2015', 'journal-title': 'Cleve Clin J Med'}, { 'issue': '4', 'key': '10.1016/j.pharma.2022.08.013_bib0255', 'doi-asserted-by': 'crossref', 'first-page': '561', 'DOI': '10.1016/j.pop.2017.07.001', 'article-title': 'Gastroesophageal reflux disease', 'volume': '44', 'author': 'Kellerman', 'year': '2017', 'journal-title': 'Prim Care'}, { 'issue': '4', 'key': '10.1016/j.pharma.2022.08.013_bib0260', 'first-page': '265', 'article-title': 'Epidemiological study assessing the overuse of proton pump inhibitors ' 'in Lebanese population', 'volume': '12', 'author': 'Hoteit', 'year': '2020', 'journal-title': 'Middle East J Dig Dis'}, { 'issue': '9', 'key': '10.1016/j.pharma.2022.08.013_bib0265', 'doi-asserted-by': 'crossref', 'first-page': '611', 'DOI': '10.1016/j.gastre.2021.04.003', 'article-title': 'Proton pump inhibitors in the COVID-19 pandemic', 'volume': '44', 'author': 'Sebastián Domingo', 'year': '2021', 'journal-title': 'Gastroenterología y Hepatología (English Edition)'}, { 'issue': '4', 'key': '10.1016/j.pharma.2022.08.013_bib0270', 'doi-asserted-by': 'crossref', 'first-page': '228', 'DOI': '10.15171/mejdd.2017.78', 'article-title': 'The Association between modulating inflammatory cytokines and ' 'constipation of geriatrics in Iran', 'volume': '9', 'author': 'Mokhtare', 'year': '2017', 'journal-title': 'Middle East J Dig Dis'}, { 'issue': '5', 'key': '10.1016/j.pharma.2022.08.013_bib0275', 'doi-asserted-by': 'crossref', 'first-page': '2333', 'DOI': '10.1007/s11357-021-00397-z', 'article-title': 'Therapeutic prevention of COVID-19 in elderly: a case-control study', 'volume': '43', 'author': 'Blanc', 'year': '2021', 'journal-title': 'Geroscience'}, { 'key': '10.1016/j.pharma.2022.08.013_bib0280', 'doi-asserted-by': 'crossref', 'first-page': '110018', 'DOI': '10.1016/j.mehy.2020.110018', 'article-title': 'Is it possible to use proton pump inhibitors in COVID-19 treatment and ' 'prophylaxis?', 'volume': '143', 'author': 'Taştemur', 'year': '2020', 'journal-title': 'Med Hypotheses'}, { 'issue': '1', 'key': '10.1016/j.pharma.2022.08.013_bib0285', 'doi-asserted-by': 'crossref', 'first-page': '76', 'DOI': '10.1136/gutjnl-2020-322248', 'article-title': 'Severe clinical outcomes of COVID-19 associated with proton pump ' 'inhibitors: a nationwide cohort study with propensity score matching', 'volume': '70', 'author': 'Lee', 'year': '2021', 'journal-title': 'Gut'}, { 'issue': '2', 'key': '10.1016/j.pharma.2022.08.013_bib0290', 'doi-asserted-by': 'crossref', 'first-page': '137', 'DOI': '10.1097/MEG.0000000000002013', 'article-title': 'Pre-hospitalization proton pump inhibitor use and clinical outcomes in ' 'COVID-19', 'volume': '34', 'author': 'Ramachandran', 'year': '2022', 'journal-title': 'Eur J Gastroenterol Hepatol'}, { 'issue': '11', 'key': '10.1016/j.pharma.2022.08.013_bib0295', 'doi-asserted-by': 'crossref', 'first-page': 'e0241955', 'DOI': '10.1371/journal.pone.0241955', 'article-title': 'Prognostic factors for severity and mortality in patients infected with ' 'COVID-19: a systematic review', 'volume': '15', 'author': 'Izcovich', 'year': '2020', 'journal-title': 'PLOS ONE'}, { 'issue': '1', 'key': '10.1016/j.pharma.2022.08.013_bib0300', 'doi-asserted-by': 'crossref', 'first-page': '10', 'DOI': '10.7883/yoken.JJID.2021.074', 'article-title': 'Does proton pump inhibitor use lead to a higher risk of coronavirus ' 'disease 2019 infection and progression to severe disease? A ' 'meta-analysis', 'volume': '75', 'author': 'Yan', 'year': '2022', 'journal-title': 'Jpn J Infect Dis'}, { 'issue': '6', 'key': '10.1016/j.pharma.2022.08.013_bib0305', 'doi-asserted-by': 'crossref', 'first-page': '582', 'DOI': '10.3390/v12060582', 'article-title': 'Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2', 'volume': '12', 'author': 'Younes', 'year': '2020', 'journal-title': 'Viruses'}, { 'issue': '6', 'key': '10.1016/j.pharma.2022.08.013_bib0310', 'doi-asserted-by': 'crossref', 'first-page': '676', 'DOI': '10.1093/aje/kwq433', 'article-title': 'Updating and validating the Charlson comorbidity index and score for ' 'risk adjustment in hospital discharge abstracts using data from 6 ' 'countries', 'volume': '173', 'author': 'Quan', 'year': '2011', 'journal-title': 'Am J Epidemiol'}, { 'issue': '4', 'key': '10.1016/j.pharma.2022.08.013_bib0315', 'doi-asserted-by': 'crossref', 'first-page': '442', 'DOI': '10.1016/j.annemergmed.2020.07.022', 'article-title': 'Development and validation of the quick COVID-19 Severity Index: a ' 'prognostic tool for early clinical decompensation', 'volume': '76', 'author': 'Haimovich', 'year': '2020', 'journal-title': 'Ann Emerg Med'}, { 'issue': '1', 'key': '10.1016/j.pharma.2022.08.013_bib0320', 'doi-asserted-by': 'crossref', 'first-page': '22402', 'DOI': '10.1038/s41598-020-80061-2', 'article-title': 'A meta-analysis of accuracy and sensitivity of chest CT and RT-PCR in ' 'COVID-19 diagnosis', 'volume': '10', 'author': 'Khatami', 'year': '2020', 'journal-title': 'Sci Rep'}, { 'issue': '1', 'key': '10.1016/j.pharma.2022.08.013_bib0325', 'first-page': 'e12759', 'article-title': 'Adverse effects associated with proton pump inhibitor use', 'volume': '13', 'author': 'Yibirin', 'year': '2021', 'journal-title': 'Cureus'}, { 'issue': '4', 'key': '10.1016/j.pharma.2022.08.013_bib0330', 'doi-asserted-by': 'crossref', 'first-page': '230', 'DOI': '10.32598/ppj.24.4.40', 'article-title': 'Proton pump inhibitors in Iranian population: from clinical regimens to ' 'pharmacogenomics', 'volume': '24', 'author': 'Bagherzadeh', 'year': '2020', 'journal-title': 'Physiol Pharmacol'}, { 'issue': '8', 'key': '10.1016/j.pharma.2022.08.013_bib0335', 'doi-asserted-by': 'crossref', 'first-page': '1638', 'DOI': '10.14309/ajg.0000000000001311', 'article-title': 'Increased ACE2 levels and mortality risk of patients with COVID-19 on ' 'proton pump inhibitor therapy', 'volume': '116', 'author': 'Liu', 'year': '2021', 'journal-title': 'Am J Gastroenterol'}, { 'issue': '6', 'key': '10.1016/j.pharma.2022.08.013_bib0340', 'doi-asserted-by': 'crossref', 'first-page': '1642', 'DOI': '10.1007/s43440-021-00263-x', 'article-title': 'Proton pump inhibitor on susceptibility to COVID-19 and its severity: a ' 'systematic review and meta-analysis', 'volume': '73', 'author': 'Pranata', 'year': '2021', 'journal-title': 'Pharmacol Rep'}, { 'issue': '9', 'key': '10.1016/j.pharma.2022.08.013_bib0345', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.cgh.2021.05.011', 'article-title': 'Proton Pump inhibitor use is not strongly associated with SARS-CoV-2 ' 'related outcomes: a nationwide study and meta-analysis', 'volume': '19', 'author': 'Israelsen', 'year': '2021', 'journal-title': 'Clin Gastroenterol Hepatol'}, { 'issue': '10', 'key': '10.1016/j.pharma.2022.08.013_bib0350', 'doi-asserted-by': 'crossref', 'first-page': '1707', 'DOI': '10.14309/ajg.0000000000000798', 'article-title': 'Increased risk of COVID-19 among users of proton pump inhibitors', 'volume': '115', 'author': 'Almario', 'year': '2020', 'journal-title': 'Am J Gastroenterol'}, { 'issue': '12', 'key': '10.1016/j.pharma.2022.08.013_bib0355', 'doi-asserted-by': 'crossref', 'first-page': '1410', 'DOI': '10.1016/j.dld.2020.10.001', 'article-title': 'Proton pump inhibitor use is associated with increased risk of severity ' 'and mortality from coronavirus disease 2019 (COVID-19) infection', 'volume': '52', 'author': 'Hariyanto', 'year': '2020', 'journal-title': 'Dig Liver Dis'}, { 'issue': '1', 'key': '10.1016/j.pharma.2022.08.013_bib0360', 'doi-asserted-by': 'crossref', 'first-page': '125', 'DOI': '10.1111/joim.13183', 'article-title': 'Use of proton pump inhibitors and risk of adverse clinical outcomes ' 'from COVID-19: a meta-analysis', 'volume': '289', 'author': 'Kow', 'year': '2021', 'journal-title': 'J Intern Med'}, { 'key': '10.1016/j.pharma.2022.08.013_bib0365', 'doi-asserted-by': 'crossref', 'first-page': '287', 'DOI': '10.2147/JIR.S292303', 'article-title': 'Analysis of the effect of proton-pump inhibitors on the course of ' 'COVID-19', 'volume': '14', 'author': 'Zhang', 'year': '2021', 'journal-title': 'J Inflamm Res'}, { 'issue': '12', 'key': '10.1016/j.pharma.2022.08.013_bib0370', 'doi-asserted-by': 'crossref', 'first-page': '2763', 'DOI': '10.12998/wjcc.v9.i12.2763', 'article-title': 'Paradoxical relationship between proton pump inhibitors and COVID-19: a ' 'systematic review and meta-analysis', 'volume': '9', 'author': 'Zippi', 'year': '2021', 'journal-title': 'World J Clin Cases'}, { 'key': '10.1016/j.pharma.2022.08.013_bib0375', 'series-title': 'Encyclopedia of Respiratory Medicine', 'article-title': 'PNEUMONIA\xa0|\xa0Nosocomial', 'author': 'Torres', 'year': '2006'}, { 'issue': '6', 'key': '10.1016/j.pharma.2022.08.013_bib0380', 'doi-asserted-by': 'crossref', 'first-page': '1010', 'DOI': '10.1136/gutjnl-2020-320953', 'article-title': 'Digestive system is a potential route of COVID-19: an analysis of ' 'single-cell coexpression pattern of key proteins in viral entry process', 'volume': '69', 'author': 'Zhang', 'year': '2020', 'journal-title': 'Gut'}, { 'issue': '2', 'key': '10.1016/j.pharma.2022.08.013_bib0385', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a ' 'clinically proven protease inhibitor', 'volume': '181', 'author': 'Hoffmann', 'year': '2020', 'journal-title': 'Cell'}, { 'issue': '3', 'key': '10.1016/j.pharma.2022.08.013_bib0390', 'doi-asserted-by': 'crossref', 'first-page': 'e580', 'DOI': '10.1002/iid3.580', 'article-title': 'The relationship between COVID-19 viral load and disease severity: a ' 'systematic review', 'volume': '10', 'author': 'Dadras', 'year': '2022', 'journal-title': 'Immun Inflamm Dis'}, { 'issue': '13', 'key': '10.1016/j.pharma.2022.08.013_bib0395', 'doi-asserted-by': 'crossref', 'first-page': '12493', 'DOI': '10.18632/aging.103579', 'article-title': 'Epidemiological, comorbidity factors with severity and prognosis of ' 'COVID-19: a systematic review and meta-analysis', 'volume': '12', 'author': 'Fang', 'year': '2020', 'journal-title': 'Aging (Albany NY)'}, { 'issue': '2', 'key': '10.1016/j.pharma.2022.08.013_bib0400', 'doi-asserted-by': 'crossref', 'first-page': '428', 'DOI': '10.1111/all.14657', 'article-title': 'Risk factors for severe and critically ill COVID-19 patients: a review', 'volume': '76', 'author': 'Gao', 'year': '2021', 'journal-title': 'Allergy'}], 'container-title': 'Annales Pharmaceutiques Françaises', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0003450922001122?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0003450922001122?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 3, 17]], 'date-time': '2023-03-17T03:00:16Z', 'timestamp': 1679022016000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0003450922001122'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 3]]}, 'references-count': 40, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2023, 3]]}}, 'alternative-id': ['S0003450922001122'], 'URL': 'http://dx.doi.org/10.1016/j.pharma.2022.08.013', 'relation': {}, 'ISSN': ['0003-4509'], 'subject': [], 'container-title-short': 'Annales Pharmaceutiques Françaises', 'published': {'date-parts': [[2023, 3]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'What is the role of proton pump inhibitors consumption on the clinical ' 'presentation and severity of COVID-19 infection?', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Annales Pharmaceutiques Françaises', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.pharma.2022.08.013', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All ' 'rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit